LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
S-E. Al-Batran(University Hospital Frankfurt), Z.A. Wainberg(Olive View-UCLA Medical Center), K. Muro(Aichi Cancer Center), D. Molena(Memorial Sloan Kettering Cancer Center), E. Van Cutsem(KU Leuven), Woo Jin Hyung(Yonsei University), L.S. Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), M. Moehler, F. Rivera Herrero(Instituto de Investigación Marqués de Valdecilla), D-Y. Oh(Seoul National University Hospital), Takeshi Omori(Osaka International Cancer Institute), E.C. Smyth(Churchill Hospital), M. Liberman(Centre Hospitalier de l’Université de Montréal), Annette Stein(University Cancer Center Hamburg), Muammer Bilici(Atatürk University), Oscar K. Serrano, Eric Heilbron, F. Hernandorena, J. Tabernero, Y. Y. Janjigian
Cited by 5Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis